Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9vHPV 2-dose extended-interval regimen study in children and adolescents versus 3-dose regimen in young women
2020-003736-24Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoint: Geometric mean titers of anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies. Started Dec 2020; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2020-003736-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003736-24.